Recent areas of supported research include the rapid impact of GLP-1s, the effect of policy on prescription opioid utilization and treatment, and advancements in the use of innovative technology in healthcare.
Research Support
Support for empirically rigorous, actionable, and policy-relevant studies to advance the field of Human Data Science through partnerships with academic researchers from a variety of disciplines, including pharmacy, medicine, economics, and public policy.
Recent areas of supported research include the rapid impact of GLP-1s, the effect of policy on prescription opioid utilization and treatment, and advancements in the use of innovative technology in healthcare.
Research priorities
The IQVIA Institute welcomes proposals examining most aspects of healthcare with the following high-priority areas of utmost interest:
- Health Economics Research
- Drug Utilization Trends and Expenditure
- Health Services Research
- Advancing Public Health
- Drug Development and Innovation
Health Economics Research
- Cost-effectiveness and drug pricing
- Health plan design and reimbursement models
- Incentives, market changes, and regulation
- Economic policy impact at regional, national, and international levels
Drug Utilization Trends and Expenditures
- National trends in prescription drug utilization and office-based care
- Adoption of new therapies among patient and physician subpopulations
- Prescription use and expenditures, and factors that influence these trends
- Supply chain disruptions and changes
Health Services Research
- Quality, safety, and outcomes of care
- Provider behavior and practice variation
- Healthcare utilization and spending
- Care coordination and system design
- Disparities in delivery and outcomes
Advancing Public Health
- Socio-economic disparities in processes and outcomes of care
- Disparities in access to medicine or healthcare based on race, ethnicity, or income
- Studies of diseases which embed inherent socioeconomic impact on morbidity or epidemiological variations due to race or ethnicity
Drug Development and Innovation
- Drug development pipelines
- Drug pricing and launch strategies
- Patent cliffs, generics, and biosimilars
- Orphan drugs and rare diseases
How Researchers Can Benefit from IQVIA Data
Through collaboration with the IQVIA Institute, researchers have access to a broad range of proprietary databases and tools to support independent research, discovery work, and requirement development for future funded studies.
Our goal is to partner with researchers who have professional recognition, exposure, and funding to sustain a steady stream of influential research. Through these valuable partnerships, we can continue to optimize the application of our assets and make a positive impact on public health, health policy, and healthcare delivery.
To this end, IQVIA information can be made available at pricing tailored to the academic research community for approved researchers conducting studies in health services.
Learn more about available data here: Available IQVIA Data.
Below are the most frequently requested U.S.-based datasets.
IQVIA Real World Data
- Non-identifiable patient activity across healthcare channels, including Prescription Claims (LRx), Lifecycle Prescription Claims (LAAD), Unadjudicated Medical Claims (Dx), Ambulatory EMR, Oncology EMR, and health plan informed Closed Claims (Pharmetrics+)
- Over 300Mn anonymous patients
- Data available starting with the early 2000s
- Data can be linked (for example, prescription claims and medical claims) via the unique non-identified patient ID
IQVIA National and Global Data
- National Prescription Audit: Over 90% coverage from retail, mail, and long-term care pharmacies for dispensed prescriptions across all payers, including cash and projected to a national estimate; data available at the prescriber specialty level and in terms of total dispensed prescriptions and total quantities dispensed
- National Sales Perspectives: Over 90% coverage in both retail and non-retail segments of medicines distributed in the U.S. and projected to a national estimate; data are available by channel of distribution and at an NDC level
- MIDAS: Country-level sales and unit volume of medicines for 87 countries with standardized dollar and unit measures
Collaborating with the IQVIA Institute
Researchers interested in collaborating with the IQVIA Institute on specific research studies should direct questions to info@iqviainstitute.org.
In addition, we ask that the researcher provide a CV and any relevant, supplementary information. Proposals will be reviewed and evaluated based on their likely impact on healthcare, innovativeness, timeliness, methodology, practicality, and investigator qualifications. If chosen for follow-up, the Institute will schedule a time to discuss the request and determine which assets and capabilities best suit the research design and objectives.
We may also make recommendations for altering the design, when appropriate, based on our many years of experience in supporting this kind of research. This sometimes involves an iterative process to optimize the use and application of the data and to ensure the optimal result for the researcher.
If requests require grant funding to cover costs, we may provide a letter of support to help facilitate the grant application process.
Please direct questions about proposals, available data, and the application process to: info@iqviainstitute.org.
